Discover CSL Ltd's groundbreaking patent for proteins targeting the hG-CSFR receptor, paving the way for innovative antibody therapies against G-CSF signaling.

Savara says it will in the first of half next year seek an FDA license to treat autoimmune pulmonary alveolar proteinosis ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...

Recently, the use of mobilizing agents such as granulocyte colony-stimulating factor has renewed interest in these treatment modalities. Some studies have shown a benefit in neutropenic patients ...

Purpose. The efficacy and safety of granulocyte colony-stimulating factor (G-CSF) in critically ill patients with severe sepsis or septic shock were evaluated. Summary. The medical literature was ...

However, omission does result in reductions in neutropenia, thrombocytopenia, and use of granulocyte colony-stimulating factor ...

Tocilizumab -- an interleukin (IL)-6 receptor inhibitor -- was approved by the FDA in 2017 for the treatment of severe or ...

The world’s first stem cell register was set up by Shirley Nolan in her determination to save her son’s life by finding him a ...

India: A recent case report published in Cureus underscores the serious risks associated with methotrexate toxicity, ...

However, there were significant associations for bolus omission with reductions in neutropenia (10.7 versus 22.7 percent), ...